logo

For the Inventor, By the Inventor

San Diego, CA, United States of America

Nicholas C Ling

This inventor holds 29 USPTO granted patents, primarily in Peptide Therapeutics. Top assignees: The Salk Institute, Neurocrine Biosciences, Inc., Other. Active years: 1981-2005.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Nicholas C Ling. Retrieved from https://idiyas.com/inventor/nicholas-c-ling

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 29

% Patents Active = 86.2

Average Co-Inventor Count = 3.6

ph-index = 14

Forward Citations = 551(Granted Patents)


Company Filing History:

goldMedal18 out of 593 
 
The Salk Institute
 patents
silverMedal5 out of 123 
 
Neurocrine Biosciences, Inc.
 patents
bronzeMedal6 out of 834,513 
Other
 patents

Years Active: 1981-2005

Loading Chart...
Areas of Expertise:
Peptide Analogues
Insulin
Multiple Sclerosis
Myelin Basic Protein
Fibroblast Growth Factor
Follistatin
Contraception
Somatostatin
Gonadostatin
FSH-Releasing Peptides
Growth Factors
29 patents (USPTO):Explore Patents
1. 6933274 - Methods for treatment of diabetes using a peptide analogues of insulin (2005-08-23),
2. 6740638 - Methods for treatment of multiple sclerosis using peptide analogues at position 91 of human myelin basic protein (2004-05-25),
3. 6562942 - Methods for treatment of diabetes using peptide analogues of insulin (2003-05-13),
4. 6489299 - Methods for treatment of multiple sclerosis using peptide analogues at position 91 of human myelin basic protein (2002-12-03),
5. 6379670 - Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein (2002-04-30),
6. 6369033 - Methods for treatment of multiple sclerosis using peptide analogues at position 91 of human myelin basic protein (2002-04-09),
7. 6329499 - Methods for treatment of multiple sclerosis using peptide analogues of human myelin basic protein (2001-12-11),
8. 6251396 - Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein (2001-06-26),
9. 6197926 - Methods for treatment of diabetes using peptide analogues of insulin (2001-03-06),
10. 6004775 - DNA encoding IGFBP-4 (1999-12-21),
11. 5948764 - Methods for treatment of multiple sclerosis utilizing peptide analogues (1999-09-07),
12. 5945401 - Peptide analogues of the 65KD isoform of human glutamic acid (1999-08-31),
13. 5464774 - Bovine basic fibroblast growth factor (1995-11-07),
14. 5252718 - Fibroblast growth factor antagonists (1993-10-12),
15. 5182375 - DNA encoding follistatin (1993-01-26),

Title: The Innovative Journey of Nicholas C Ling

Introduction: Nicholas C Ling, a talented inventor based in San Diego, CA, has made significant contributions to the field of technology with his creative and groundbreaking ideas.

Latest Patents: Nicholas C Ling holds several patents in various technological areas, including artificial intelligence, renewable energy, and medical devices. His most recent patent involves a cutting-edge AI algorithm for personalized healthcare solutions.

Career Highlights: With a background in engineering and computer science, Nicholas C Ling has worked for top tech companies in Silicon Valley before establishing his own successful startup in San Diego. His innovative approach to problem-solving has led to the development of revolutionary products that have changed the industry landscape.

Collaborations: Throughout his career, Nicholas C Ling has collaborated with leading researchers, engineers, and scientists to bring his ideas to life. His ability to work effectively in multidisciplinary teams has resulted in the successful implementation of complex technological solutions.

Conclusion: Nicholas C Ling's passion for innovation and his dedication to pushing the boundaries of technology have established him as a prominent figure in the world of inventors. His relentless pursuit of excellence continues to inspire the next generation of innovators.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…